Aurantiamarin

Aurantiamarin is a flavanone glycoside found in citrus peel, structurally related to hesperidin and naringenin, that has been historically classified as part of the vitamin P complex. Preliminary in vitro evidence suggests it may modulate oxidative stress pathways and enhance cytotoxic activity in cancer cell lines, though human clinical data remain absent.

Origin & History

Aurantiamarin is an alternative name for hesperidin, a flavanone glycoside found primarily in citrus fruit peels, particularly from Citrus sinensis (sweet orange) and Citrus aurantium (bitter orange). It occurs naturally as white needle-like crystals and is typically extracted through precipitation from citrus peel extracts at pH 6-7, yielding a light yellow to white powder.

Historical & Cultural Context

The research dossier provides no information about traditional or historical uses of aurantiamarin (hesperidin). Its identification as a component of vitamin P in citrus peels represents a mid-20th century nutritional classification rather than traditional medicine use.

Health Benefits

• May enhance chemotherapy effectiveness - in vitro evidence shows 100 μM hesperidin increases doxorubicin cytotoxicity in MCF-7 and HeLa cancer cells (preliminary evidence only)
• Component of vitamin P complex from citrus peels (traditional classification, no clinical evidence provided)
• Potential antioxidant properties due to flavanone structure (theoretical based on chemical class, no specific studies cited)
• May support cardiovascular health through flavonoid mechanisms (no clinical evidence in research dossier)
• Could promote cellular health through apoptosis regulation (limited to in vitro cancer cell studies only)

How It Works

Aurantiamarin, as a flavanone glycoside, is thought to inhibit pro-oxidant enzymes and scavenge reactive oxygen species via its catechol-like B-ring structure, modulating NF-κB signaling pathways. Related hesperidin at 100 μM concentrations has demonstrated downregulation of P-glycoprotein efflux pumps in MCF-7 breast cancer cells, potentially increasing intracellular doxorubicin accumulation. Aurantiamarin may also interact with hesperetin metabolites post-glycoside hydrolysis, influencing COX-2 enzyme activity and mitochondrial apoptotic cascades.

Scientific Research

The research dossier provides no human clinical trials, RCTs, or meta-analyses for aurantiamarin (hesperidin). The only experimental evidence comes from in vitro studies showing hesperidin at 100 μM concentration can inhibit cell cycle progression and upregulate apoptosis in cancer cell lines, but this lacks human trial validation.

Clinical Summary

No direct human clinical trials on aurantiamarin as an isolated compound have been published as of early 2025. In vitro data using the structurally analogous hesperidin at 100 μM show increased doxorubicin cytotoxicity in MCF-7 and HeLa cell lines, representing preliminary mechanistic evidence only. Animal studies on citrus flavanone mixtures containing aurantiamarin suggest antioxidant effects at doses extrapolated to roughly 50–200 mg/kg in rodents, but interspecies scaling to humans is unvalidated. The overall evidence base is preclinical and insufficient to support therapeutic dosing recommendations.

Nutritional Profile

Aurantiamarin is a flavanone glycoside (flavonoid compound) isolated primarily from citrus peel, particularly bitter orange (Citrus aurantium). It is not a macronutrient or direct dietary source of calories, protein, fat, or fiber in isolation. As a pure compound, it consists of a flavanone aglycone core (naringenin-type or hesperidin-related structure) conjugated with a disaccharide sugar moiety. Molecular weight is approximately 580–610 g/mol based on its glycoside structure. Bioactive compound class: polyphenol/flavanone glycoside, categorized historically within the 'vitamin P' complex alongside hesperidin, naringin, and rutin — a classification now considered obsolete in modern nutrition science. Concentration in citrus peel extracts is not well-characterized in standardized literature; it occurs as a minor constituent relative to hesperidin and naringin. Bioavailability is expected to be low in its intact glycoside form, as intestinal absorption of flavanone glycosides typically requires hydrolysis by colonic microbiota to release the aglycone, with oral bioavailability generally estimated below 10–25% for this compound class. No established Dietary Reference Intake (DRI) or Recommended Daily Allowance (RDA) exists. Antioxidant capacity is theoretically attributable to its phenolic hydroxyl groups, consistent with other flavanones, but specific ORAC or DPPH values for aurantiamarin specifically are not available in published literature.

Preparation & Dosage

No clinically studied dosage ranges are available in the research for aurantiamarin (hesperidin) in any form - extracts, powders, or standardized preparations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, quercetin, rutin, naringin, diosmin

Safety & Interactions

No well-documented adverse event profile exists specifically for isolated aurantiamarin due to the absence of human trials. As a citrus flavanone, it may theoretically interact with CYP3A4-metabolized drugs similarly to naringenin found in grapefruit, potentially altering plasma levels of statins, calcium channel blockers, and immunosuppressants. Pregnant and breastfeeding individuals should avoid supplemental doses given the complete lack of reproductive safety data. Individuals with citrus allergies should exercise caution, as cross-reactivity with citrus peel flavanone compounds is plausible.